To print: Select File and then Print from your browser's menu

Title: Vegamox(TM) (Moxifloxacin Hydrochloride Ophthalmic Solution) Approved in Japan for Eye Infections

"Vegamox(TM) (Moxifloxacin Hydrochloride Ophthalmic Solution) Approved in Japan for Eye Infections"

FORT WORTH, TX -- July 27, 2006 -- Alcon, Inc. announced that the Ministry of Health, Labor and Welfare in Japan has approved its Vegamox™ (moxifloxacin hydrochloride ophthalmic solution) 0.5 % for the treatment of bacterial infections of the eye including, among others, conjunctivitis and keratitis (including corneal ulcer), as well as for surgical prophylaxis. Vegamox solution is a fourth-generation fluoroquinolone eye drop formulated at a 0.5% concentration, providing high drug concentration throughout relevant ocular structures. Its near-neutral pH of 6.8 provides for ocular comfort. In clinical studies, Vegamox solution has demonstrated excellent efficacy and therapeutic penetration. Alcon Japan President Scott Manning said the approval will present an opportunity for increased sales in Japan, the world's second largest ocular anti-infective market. "The approval of Vegamox solution provides Alcon Japan with an important opportunity to expand its pharmaceutical offerings in Japan to include anti-infectives and more fully serve Japanese ophthalmologists," said Manning. "Because of its clinical profile and our experience with it in the U.S., where it is the number one prescribed ocular anti-infective, as well as the strong preference for fluoroquinolones by Japanese ophthalmologists, we expect it to be a strong participant in the anti-infective market in Japan. In anticipation of the commercial launch of Vegamox(TM) solution this year, we are expanding our sales force in order to reach physicians with information about how this product may contribute to the treatment of bacterial eye diseases." Vegamox solution is currently approved as Vigamox™ solution in more than 40 countries around the world. SOURCE: Alcon, Inc.

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.